A virtual cancer cell that predicts what a drug will do before you test it
Train a model on millions of experiments where genes and drugs were altered, so it can predict the effect of a new combination without running the experiment.
Perturbation foundation models trained on Perturb-seq, CRISPR screens and compound-response atlases aim to predict transcriptional and viability responses to unseen perturbations and combinations. The critical missing element is prospective, blinded validation against held-out wet-lab experiments and, eventually, clinical outcomes. Without that, these models risk repeating the overfitting seen in earlier drug-response prediction efforts.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
- AI that is built but not validated or deployed · Thousands of cancer AI models are published; a handful are in clinical use, and fewer have shown they help patients.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
Pages like this
not linked directly; found by shared links- TechnologyPhenom-2 and Recursion OS
Shares Recursion Pharmaceuticals, AI-driven drug & target discovery, CRISPR functional genomics.
- IdeaIn silico trials to choose the dose before the first patient
Shares Insilico Medicine, AI-driven drug & target discovery, Preclinical models that do not predict people.
- IdeaSelf-driving laboratories that run the cancer biology hypothesis loop autonomously
Shares Recursion Pharmaceuticals, AI-driven drug & target discovery, CRISPR functional genomics, Preclinical models that do not predict people.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares Insilico Medicine, AI-driven drug & target discovery.
- IdeaAn open foundation model of the cancer cell trained on perturbation data
Shares AI-driven drug & target discovery, CRISPR functional genomics, Too many combinations to test, AI that is built but not validated or deployed.
- TechnologyBoltz-1 / Boltz-2 (MIT, open)
Shares Recursion Pharmaceuticals, AI-driven drug & target discovery.
- IdeaWhole-patient digital twins validated in prospective randomised trials
Shares Too many combinations to test, AI that is built but not validated or deployed, Preclinical models that do not predict people.
- IdeaScore every model system on how well it predicted real trial results
Shares AI-driven drug & target discovery, AI that is built but not validated or deployed, Preclinical models that do not predict people.